Thrombosis is one of the major causes of death worldwide. It occurs due to imbalance between prothrombotic and fibrinolytic pathway. The clot formation activates the endogenous fibrinolytic system, for conversion of plasminogen to plasmin. Plasmin degrades the fibrin clot, restoring blood flow to vital organs. Thus, fibrinolysis is a physiological mechanism designed to remove intravascular thrombi while maintaining vascular patency. Several fibrinolytic drugs such as Streptokinase, recombinant t-PA and Reteplase are used clinically, principally to reperfuse the occluded coronary artery in diseases such as angina pectoris. However, these thrombolytics have many shortcomings such enhanced risk of bleeding such as GI haemorrhage. Present study was carried out for evaluation of potato tuber carboxypeptidase inhibitor, which is an inhibitor of thrombin activatable fibrinolysis inhibitor (TAFI) a newer target for fibrinolytic drugs which inhibits the conversion of plasminogen to plasmin with other standard drugs like aspirin and clopidogrel in models of thrombososis and coagulation.
|Journal||International Journal of Pharma and Bio Sciences|
|Publication status||Published - 2010|
Bhatt, S., Pandey, D. K., & Pai, K. S. R. (2010). Evaluation of potato tuber carboxypeptidase inhibitor with standard anti-thrombotic drugs in various thrombosis models. International Journal of Pharma and Bio Sciences, 1(1). https://www.scopus.com/inward/record.uri?eid=2-s2.0-82755192216&partnerID=40&md5=22558d82210e09ffb0b53a16b355624e